^
Association details:
| Biomarker: | SLC22A3 expression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors
Published date:
09/19/2023
Excerpt:
In HCC samples, OCT3 was expressed at the PM of cancer cells, and its presence, detected in 26% of tumors, was associated with better outcomes in patients treated with sorafenib.
DOI:
10.1016/j.bcp.2023.115812